Paige, a global leader in AI-based diagnostic software in pathology, today announced it has appointed Andy Moye, Ph.D. as Chief Commercial Officer and Juan Antonio Retamero, M.D. as Medical Director as the company enters its next phase of growth.
“We are excited to welcome Andy and Juan to Paige as we rapidly expand our commercial and medical functions to meet the growing demand for our portfolio of digital pathology products,” said Leo Grady, Ph.D., Chief Executive Officer of Paige. “On the heels of a successful Series C financing round, Andy and Juan will be instrumental in shaping our growth strategy as we expand into new markets across the globe.”
Dr. Moye is a seasoned commercial leader and corporate development executive who has worked across the molecular diagnostics, biotechnology and life sciences industries. Notably, he served as Head of Commercial Operations in North America and Latin America for Philips where he led commercial operations for digital pathology solutions, delivering significant growth in both markets for emerging business. Dr. Moye has also served in executive roles at leading healthcare companies including Ontada, a division of McKesson, Caris Life Sciences and WaferGen Bio-systems, now part of Takara Bio. At Paige, he will lead the company’s clinical sales and commercial strategy.
“Paige is creating truly a disruptive technology platform, and I am thrilled to help bring this technology to the clinic to benefit pathologists, oncologists and ultimately patients with cancer,” said Dr. Moye. “It is a dream job to work at the intersection of oncology, genomics, pathology and data and an exciting culmination of my work over the past few decades.”
Dr. Retamero is an internationally-recognized pathologist and a leading expert on the implementation and use of digital pathology tools for routine clinical diagnosis. As a digital pathology pioneer, he has broad international expertise in the modernization of the profession. He will lead Paige’s clinical and evidence development strategy and relationships with clinical and health economic leaders.
“Modernizing pathology is long overdue, and I am excited to join Paige to help transform how pathologists work and, ultimately, improve patients’ lives,” said Dr. Retamero. “As pathologists continue to experience rising caseloads and increasing complexity, Paige is well-suited to address these challenges, with digital and computational pathology becoming an increasingly critical component of the practice.”
About Paige
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc. and colleagues from Memorial Sloan Kettering Cancer Center (MSK). The company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of AI-based technologies positioned to drive the future of diagnostics, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s products deliver insights to pathologists and oncologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products.
For additional information, please visit: https://www.Paige.ai, https://www.paigeplatform.com, Twitter and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210330005400/en/